

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 May 2026

The effect of resveratrol supplementation on clinical parameters and inflammatory markers in diabetic patients with chronic periodontitis

Protocol summary

Study aim

Determining the effect of resveratrol supplementation on periodontal status and inflammatory markers in diabetic patients with chronic periodontitis

Design

A clinical trial with a control group, with parallel groups, double-blind, randomized, phase 2 on 52 patients. The random assignment of samples to the intervention and control groups will be randomly stratified (stratified randomization).

Settings and conduct

Non-surgical periodontal treatment will be performed for 52 diabetic patients with moderate to severe chronic periodontitis (26 case group, 26 control group) and for 4 weeks, one capsule of 600 mg of resveratrol will be given to the case group and control group patients They will receive 600 mg placebo tablets containing starch every day. All clinical parameters will be measured 4 weeks and 3 months after the intervention in recalling the patients.

Participants/Inclusion and exclusion criteria

Inclusion criteria: age 30-60 years, body mass index 18.5 to 30 kg/m², patients with confirmed diabetes mellitus controlled HBA1C>9, and moderate to severe periodontal disease. Exclusion criteria: non-cooperation, kidney failure, systemic disease, drug use, pregnancy and breastfeeding, smoking, allergy to black grapes or blueberries.

Intervention groups

Non-surgical periodontal treatment will be performed for 52 diabetic patients with moderate to severe chronic periodontitis (26 case group, 26 control group) and for 4 weeks, one capsule of 600 mg of resveratrol will be given to the case group and control group patients They will receive 600 mg placebo tablets containing starch every day. All clinical parameters will be measured 4 weeks and 3 months after the intervention in recalling the patients.

Main outcome variables

Probing depth, clinical attachment level, plaque index, bleeding index, and the amount of IL-8 and IL-1 β in saliva.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20171015036782N9**

Registration date: **2023-02-14, 1401/11/25**

Registration timing: **prospective**

Last update: **2023-02-14, 1401/11/25**

Update count: **0**

Registration date

2023-02-14, 1401/11/25

Registrant information

Name

farzane vaziri

Name of organization / entity

Shahid sadoughi dental university

Country

Iran (Islamic Republic of)

Phone

+98 35 3620 4764

Email address

f.vaziri@ssu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-02-20, 1401/12/01

Expected recruitment end date

2023-06-22, 1402/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of resveratrol supplementation on clinical parameters and inflammatory markers in diabetic patients with chronic periodontitis

Public title

the effect of resveratrol on the gingival health of diabetic patients

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Age between 30-60 years Body mass index (BMI) 18.5 to 30 kg/m² Patients with confirmed and controlled diabetes mellitus (minimum one year and maximum 5 years since diagnosis) 9>HBA1C Moderate to severe periodontal disease

Exclusion criteria:

Patient non-cooperation Diabetes complications such as kidney failure No systemic disease taking medication Pregnancy and breastfeeding smoking Allergy to black grapes or blueberries

Age

From **30 years** old to **60 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **52**

Randomization (investigator's opinion)

Randomized

Randomization description

The selection of patients and study samples in diabetic and non-diabetic groups is done using the purposive sampling method. The random allocation of the samples to the treatment and control groups will be randomly stratified and based on age and gender (stratified randomization), which means that there will be no significant difference in the average age and gender frequency in the drug and placebo groups.

Blinding (investigator's opinion)

Double blinded

Blinding description

After selecting the samples, none of the sampled people will know about randomization and the process of allocation to groups. Dentists are given a table of coded numbers in advance and patients are entered into the study in the order of the numbers in the table. Therefore, the present study is double-blind. Resveratrol and placebo tablets are the same in terms of shape, color and size and are delivered to the patient in the package.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Yazd University of Medical Sciences

Street address

Shahid Bahonar square

City

Yazd

Province

Yazd

Postal code

۸۹۱۶۹۷۸۴۷۷

Approval date

2022-07-11, 1401/04/20

Ethics committee reference number

IR.SSU.DENTISTRY.REC.1401.032

Health conditions studied**1****Description of health condition studied**

Chronic periodontitis

ICD-10 code

K05.3

ICD-10 code description

Chronic periodontitis

2**Description of health condition studied**

diabetes

ICD-10 code

E14

ICD-10 code description

Unspecified diabetes mellitus

Primary outcomes**1****Description**

Probing depth

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

With Probe Williams

2

Description

Clinical Attachment Level

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

With Probe Williams

3

Description

plaque index

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

The percentage of plaque accumulation around the surfaces of the teeth after evaluation with a revealing substance

4

Description

Bleeding index

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

Percentage of bleeding around all teeth after 30 seconds following probing

5

Description

IL-1 β

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

The amount of interleukin IL-1 β per unit volume of saliva

6

Description

IL-8

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

The amount of interleukin IL-8 per unit volume of saliva

Secondary outcomes

1

Description

HbA1C

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

blood test

2

Description

FBS

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

From the kit by the enzymatic method

3

Description

Body mass index

Timepoint

At the beginning of the study (before the start of the intervention) and 1 month and 3 months after the start of the study

Method of measurement

BMI is calculated using height and weight. BMI = weight (kilograms) / (height) ² (square meters)

Intervention groups

1

Description

Intervention group: 26 diabetics with moderate to severe chronic periodontitis will be selected after examination and diagnosis of periodontal symptoms and according to the entry and exit criteria and after giving the required information and obtaining written consent. After evaluating the primary and secondary outcomes, non-surgical periodontal treatment will be performed for all patients, and for patients in the 4-week case group, one 600 mg capsule (from Canada's plantvital company) will be prescribed every day during the study period with all patients 3 times in They will be contacted during the week to make sure they have taken their capsules. During the study, all patients will undergo periodontal examinations and treatments, including scaling and leveling of the root surface if needed, and the necessary training for oral and dental hygiene, including the correct way of brushing and flossing, will be given to them, and at the end of the course Patients will be re-examined after 1 month and 3 months.

Category

Treatment - Drugs

2

Description

Control group: 26 diabetics with moderate to severe chronic periodontitis will be selected after examination

and diagnosis of periodontal symptoms and according to the entry and exit criteria and after giving the required information and obtaining written consent. After evaluating the primary and secondary outcomes, non-surgical periodontal treatment will be performed for all patients, and patients in the control group will receive 600 mg placebo tablets containing starch every day. Patients will be asked to take these capsules in the morning after eating breakfast. During the study period, all patients will be contacted 3 times a week to ensure that they take their capsules. During the study, all patients will undergo periodontal examinations and treatments, including scaling and leveling of the root surface if needed, and the necessary training for oral and dental hygiene, including the correct way of brushing and flossing, will be given to them, and at the end of the course Patients will be re-examined after 1 month and 3 months.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Shahid Sadoughi University of Medical Sciences, Yazd

Full name of responsible person

Nazanin Roqani Dehkordi

Street address

Dahe Fajr St

City

Yazd

Province

Yazd

Postal code

8913893111

Phone

+98 35 2636 1000

Email

nazanin.roghani91@gmail.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Yazd University of Medical Sciences

Full name of responsible person

Mr. Dr. Hassan Mozafari

Street address

Bahner Blvd

City

Yazd

Province

Yazd

Postal code

8916844933

Phone

+98 35 2417 3393

Email

mozaffari@gmail.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Yazd University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Yazd University of Medical Sciences

Full name of responsible person

Nazanin Roqani Dehkordi

Position

Periodontics resident

Latest degree

Medical doctor

Other areas of specialty/work

Dentistry

Street address

Dahe Fajr Street

City

yazd

Province

Yazd

Postal code

8914881167

Phone

+98 35 2417 3393

Email

nazanin.roghani91@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Yazd University of Medical Sciences

Full name of responsible person

Nazanin Roqani Dehkordi

Position

Periodontics resident

Latest degree

Medical doctor

Other areas of specialty/work

Dentistry

Street address

Dahe Fajr Street

City

Yazd

Province

Yazd

Postal code

8914881167

Phone

+98 35 2417 3393

Email

nazanin.roghani91@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Yazd University of Medical Sciences

Full name of responsible person

Nazanin Roqani Dehkordi

Position

Periodontics resident

Latest degree

Medical doctor

Other areas of specialty/work

Dentistry

Street address

Dahe Fajr Street

City

yazd

Province

Yazd

Postal code

8914881167

Phone

+98 35 2417 3393

Email

nazanin.roghani91@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Only a part of the data, such as the information related to the main result or the like, can be shared.

When the data will become available and for how long

The access period starts 6 months after the results are published

To whom data/document is available

It will be available only to researchers working in academic and scientific institutions

Under which criteria data/document could be used

If periodontal and resveratrol treatments affect the severity of diabetes because by providing effective solutions to improve oral and dental health and emphasizing more on hygiene, it is possible to reduce the severity of diabetes and impose heavier costs of this disease in material terms. and spiritually prevented

From where data/document is obtainable

Conductors of the research project

What processes are involved for a request to access data/document

The request for data requires written consent from all the implementers of the research project.

Comments